A novel predictive tool, known as the Madrid Genotype Score, is able to accurately to assess the probability of a positive genetic test result in patients with non-ischemic dilated cardiomyopathy (DCM) and isolated left ventricular systolic dysfunction (LVSD) based on readily available clinical and electrocardiogram (ECG) characteristics, research suggests.